一分钟看懂
这是一项关于结直肠癌的III 期研究，登记的药物或干预包括SHR-A1811, Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab；Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab，当前状态为招募中。登记地点显示中国北京有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
SHR-A1811, Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab；Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing cancer Hospital · 北京
公开的入选条件
- 1. Subjects voluntarily enroll in the study, sign informed consent, demonstrate good compliance and cooperate with follow-up visits.
- 2. Aged between 18 and 75 years inclusive, male or female.
- 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- 4. Estimated survival expectancy ≥ 12 weeks.
- 5. Histologically or cytologically confirmed colorectal adenocarcinoma.
- 6. No prior systemic anti-tumor therapy.
- 7. Tumor tissue specimen must be provided, either archived within 1 year prior to first study treatment or newly collected fresh specimen.
- 8. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1; the measurable lesion shall not have received prior local therapy such as radiotherapy.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07676162；登记信息更新于 2026-09-10。